BioDiscovery release new analysis software program for cancer research Affymetrix and BioDiscovery Click to read more about the treatment.

Affymetrix, BioDiscovery release new analysis software program for cancer research Affymetrix and BioDiscovery, Inc. ‘CytoScan Cytogenetics OncoScan and Suite FFPE Assay Package are key elements of our cancer portfolio,’ says Dr. Andy Last, Executive Vice Chief and President Operating Officer in Affymetrix Click to read more about the treatment . ‘Researchers have been getting CNVs and copy neutral adjustments in liquid and solid tumor samples. By using Nexus Copy Number, an advanced discovery device for interrogating huge data sets, experts have been in a position to identify biomarkers that drive disease progression. The new Nexus Copy Quantity for Affymetrix software gives researchers a version of the Nexus Copy Number software that’s simpler to access and has been specifically tailored for Affymetrix' assays.’ Related StoriesNew findings reveal association between colorectal tumor and melanoma drug treatmentMeat-rich diet may increase kidney cancer riskFDA grants accelerated authorization for Tagrisso to treat patients with advanced NSCLC’We are thrilled to extend our relationship with Affymetrix through this original product,’ said Dr.